AcelRx Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AcelRx Pharmaceuticals, Inc.
Eton Pharmaceuticals gets untitled letter for promotion of its Alkindi Sprinkle hydrocortisone granules for treatment of pediatric adrenal insufficiency. The agency sent two letters last year objecting to sponsored links after a decade pause.
Animated banner ad claiming administration of Neulasta with Amgen’s Onpro on-body injector has less risk of febrile neutropenia than administration via prefilled syringe draws untitled letter and a rare press release. FDA says claims could undermine confidence in biosimilar pegfilgrastim products.
Following accelerated approval of Biogen’s Alzheimer’s drug aducanumab in the US, we look back at 10 of the FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
- Specialty Pharmaceuticals
- Controlled Release